XORTX Therapeutics shares are trading higher after the company outlined its anticipated IND application submission to the FDA for the XRx-026 gout program.

Benzinga Newsdesk www.benzinga.com Positive 94.6%

Neg 0% Neu 0% Pos 94.6%

Comments

No comments yet. Be the first!